Education
PhD，Peking Union Medical College，2011.08-2016.07
Visiting Scholar, New York Institute of Technology，2014.09-2015.06
MD，Qingdao University，2006.08-2011.07
Research and Clinical Word
2021.12-Present, Peking University Third Hospital, Associate Researcher
2016.08-2021.11, Fuwai Hospital, Chinese Academy of Medical Sciences, Resident and Attending Physician
Award and Honor
2023 Huaxia Medical Science and Technology Award First Prize
2023 "Beijing Outstanding Young Talents" (Beijing Municipal Science and Technology Commission)
2021 "Young and Middle-aged Cardiovascular Elite - Clinical Research Innovation Award" (Chinese Medical Association)
2020 "Beijing Nova Program" (Beijing Science and Technology Commission)
Dr Wang has been engaged in research on the pathogenesis of cardio-metabolic diseases and anti-thrombotic therapy in high-risk coronary heart disease patients. In previous studies, Dr Wang identified thyroid dysfunction as an independent risk factor for cardiovascular diseases and established risk stratification tools to guide clinical practice. He also explored the relevant molecular mechanisms and intervention therapy programs in the area of thyroid dysfunction and cardiovascular diseases. Dr Wang conducted RCT to explore a safe and effective individualized antiplatelet therapy strategy in high-risk coronary heart disease patients. As independent PI, he has received fundings from National Natural Science Foundation of China and Beijing Science and Technology Commission. He is currently a member of the Beijing Precision Medicine Society and serves as a reviewer for several international academic journals.
